Schear Investment Advisers LLC Acquires Shares of 378 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Schear Investment Advisers LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 378 shares of the biopharmaceutical company’s stock, valued at approximately $397,000.

Other institutional investors also recently modified their holdings of the company. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $26,000. Sachetta LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $28,000. Finally, Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals during the second quarter valued at about $33,000. 83.31% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.48% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research analyst reports. Citigroup began coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday. They issued a “neutral” rating and a $895.00 target price on the stock. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Oppenheimer decreased their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. Finally, Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Trading Down 3.3 %

Shares of REGN stock opened at $756.81 on Friday. The company has a market capitalization of $83.17 billion, a PE ratio of 18.73, a price-to-earnings-growth ratio of 2.86 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52-week low of $753.69 and a 52-week high of $1,211.20. The business’s fifty day moving average is $985.21 and its 200 day moving average is $1,033.97. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.